Assessment of platelet activation and phagocytic activity in gastric cancer patients

Table 3 Assessment of phagocytic activity of blood platelets in gastric cancer patients-E, -A, -M and in control group (mean ± SD)

	Percentage of phag-ocytizing platelets	Phagocytic index
Study group early carcinoma E1	1.08 ± 0.08	1.02 ± 0.04
	E1 vs C	E1 vs C
	P < 0.001	P < 0.001
Study group early carcinoma E2	1.27 ± 0.10	1.07 ± 0.05
	E1 vs E2	E1 vs E2
	P < 0.05	0.05 < P < 0.1
	E2 vs C	E2 vs C
	P < 0.01	P < 0.01
Study group advanced carcinoma with lymph node involvement A1	1.10 ± 0.11	1.02 ± 0.11
	A1 vs C	A1 vs C
	P < 0.001	P < 0.001
Study group advanced carcinoma with lymph node involvement A2	1.23 ± 0.08	1.03 ± 0.06
	A1 vs A2	A1 vs A2
	P < 0.05	0.7 < P < 0.8
	A2 vs C	A2 vs C
	P < 0.001	P < 0.001
Study group metastatic cancer M1	1.13 ± 0.10	1.0 ± 0.07
	M1 vs C	M1 vs C
	P < 0.001	P < 0.001
Study group metastatic cancer M2	1.20 ± 0.12	1.05 ± 0.08
	M1 vs M2	M1 vs M2
	0.2 < P < 0.3	0.7 < P < 0.8
	M2 vs C	M2 vs C
	P < 0.001	P < 0.001
Control group C	2.26 ± 0.57	1.83 ± 0.37